Last reviewed · How we verify
Menopur® Inj. — Competitive Intelligence Brief
marketed
Gonadotropin
FSH receptor and LH receptor
Reproductive Medicine / Fertility
Small molecule
Live · refreshed every 30 min
Target snapshot
Menopur® Inj. (Menopur® Inj.) — LG Life Sciences. Menopur is a purified preparation of human menopausal gonadotropins (hMG) containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) that stimulates ovarian follicle development and hormone production in women undergoing fertility treatment.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Menopur® Inj. TARGET | Menopur® Inj. | LG Life Sciences | marketed | Gonadotropin | FSH receptor and LH receptor | |
| COS with GnRH antagonists and HP-HMG | COS with GnRH antagonists and HP-HMG | Instituto Valenciano de Infertilidad, IVI VALENCIA | marketed | Gonadotropin protocol / Assisted reproductive technology regimen | GnRH receptor (antagonism); FSH receptor and LH receptor (agonism via exogenous gonadotropins) | |
| rhFSH+rhLH | rhFSH+rhLH | Fundación Santiago Dexeus Font | marketed | Gonadotropin | FSH receptor and LH receptor | |
| Follitropin alfa and lutropin alfa | Follitropin alfa and lutropin alfa | D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology | marketed | Gonadotropin | FSH receptor and LH receptor | |
| DUOSTIM | DUOSTIM | Centre Hospitalier Intercommunal Creteil | phase 3 | Gonadotropin combination therapy | FSH receptor and LH receptor | |
| Orgovyx | relugolix | MYOVANT SCIENCES | marketed | Gonadotropin Releasing Hormone Receptor Antagonist [EPC] | Gonadotropin-releasing hormone receptor | 2020-01-01 |
| Orilissa | ELAGOLIX | AbbVie | marketed | Gonadotropin Releasing Hormone Receptor Antagonist | Gonadotropin-releasing hormone receptor | 2018-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Orgovyx · 10350170 · US
- — Orgovyx · 10449191 · US
- — Orgovyx · 11583526 · US
- — Orgovyx · 11033551 · US
- — Orgovyx · 10786501 · US
Sponsor landscape (Gonadotropin class)
- Instituto Valenciano de Infertilidad, IVI VALENCIA · 4 drugs in this class
- Sisli Hamidiye Etfal Training and Research Hospital · 3 drugs in this class
- Organon and Co · 3 drugs in this class
- Fundación Santiago Dexeus Font · 3 drugs in this class
- Merck KGaA · 2 drugs in this class
- Nina la Cour Freiesleben · 2 drugs in this class
- IVI Madrid · 2 drugs in this class
- Dunamenti REK Istenhegyi IVF Center · 1 drug in this class
- D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology · 1 drug in this class
- Azienda USL Modena · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Menopur® Inj. CI watch — RSS
- Menopur® Inj. CI watch — Atom
- Menopur® Inj. CI watch — JSON
- Menopur® Inj. alone — RSS
- Whole Gonadotropin class — RSS
Cite this brief
Drug Landscape (2026). Menopur® Inj. — Competitive Intelligence Brief. https://druglandscape.com/ci/menopur-inj. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing